Abstract
Earlier this year our dear friend and colleague Professor Tony Dodi died suddenly. He was a Scientist of immense integrity and worked with many of the authors who have contributed to the current series of articles focussing on Cancer Biomarkers. His laboratory at Nottingham Trent University (NTU) authored the article entitled “NK Cells, monocytes and Non T-cell biomarkers as prognostic indicators in cancer immunotherapy” in issue 1 and he contributed enormously to the progress and wellbeing of the ENACT Research programme funded by the EU under FP6. During his career, Tony worked with Robert Lachler and Richard Bachelor at The Royal Postgraduate Medical School, Hammersmith London, prior to joining Professor Alejandro Madrigal at the Anthony Nolan Research Institute. In 2005, Tony was appointed as Professor of Haemato-oncology and Head of Leukaemia Research at NTU. He also continued to head the Immunotherapy Group at the Anthony Nolan Research Institute in London. His legacy exists in the research he undertook in the field of Cancer Immunotherapy and Transplantation Immunology and he was recently involved in the development of the Anthony Nolan Cord Blood Programme, which was developed as a result of his enthusiasm and energy. From the outset, I admired his research ability and determination and consider it to be a distinct privilege as well as pleasure to have known Tony as a colleague and close friend. He is sorely missed by all who knew him and we wish to dedicate this series of papers to his memory. We will not forget Tonys contribution to our research endeavours.
Current Cancer Therapy Reviews
Title: Dedication to Professor Tony Dodi
Volume: 4 Issue: 2
Abstract: Earlier this year our dear friend and colleague Professor Tony Dodi died suddenly. He was a Scientist of immense integrity and worked with many of the authors who have contributed to the current series of articles focussing on Cancer Biomarkers. His laboratory at Nottingham Trent University (NTU) authored the article entitled “NK Cells, monocytes and Non T-cell biomarkers as prognostic indicators in cancer immunotherapy” in issue 1 and he contributed enormously to the progress and wellbeing of the ENACT Research programme funded by the EU under FP6. During his career, Tony worked with Robert Lachler and Richard Bachelor at The Royal Postgraduate Medical School, Hammersmith London, prior to joining Professor Alejandro Madrigal at the Anthony Nolan Research Institute. In 2005, Tony was appointed as Professor of Haemato-oncology and Head of Leukaemia Research at NTU. He also continued to head the Immunotherapy Group at the Anthony Nolan Research Institute in London. His legacy exists in the research he undertook in the field of Cancer Immunotherapy and Transplantation Immunology and he was recently involved in the development of the Anthony Nolan Cord Blood Programme, which was developed as a result of his enthusiasm and energy. From the outset, I admired his research ability and determination and consider it to be a distinct privilege as well as pleasure to have known Tony as a colleague and close friend. He is sorely missed by all who knew him and we wish to dedicate this series of papers to his memory. We will not forget Tonys contribution to our research endeavours.
Export Options
About this article
Cite this article as:
Dedication to Professor Tony Dodi, Current Cancer Therapy Reviews 2008; 4 (2) . https://dx.doi.org/10.2174/157339408784310106
DOI https://dx.doi.org/10.2174/157339408784310106 |
Print ISSN 1573-3947 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-6301 |
Call for Papers in Thematic Issues
Current progress in Protein Degradation and Cancer Therapy
argeted Protein Degradation is gaining momentum in cancer therapy, it facilitate targeting undruggable proteins, it overcome cancer resistance and avoid undesirable side effects. Thus small molecules degraders have emerged as novel therapeutic strategy. Targeted protein degradation (TPD), the process of eliminating a protein of interest hold a great promise for ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Podophyllotoxin: Current Perspectives
Current Bioactive Compounds Preface [Hot Topic: Marine Natural Products (Guest Editor: Vassilios Roussis)]
Current Medicinal Chemistry Characterization of the Early CNS Stress Biomarkers and Profiles Associated with Neuropsychiatric Diseases
Current Genomics Promising Activity of Mammalian Target of Rapamycin Inhibitors in Hematologic Malignancies Therapy
Current Signal Transduction Therapy The Role of DNA Repair Pathways in AML Chemosensitivity
Current Drug Targets Self-Assembling Peptides: Potential Role in Tumor Targeting
Current Pharmaceutical Biotechnology Stem Cell Ageing and Apoptosis
Current Pharmaceutical Design Targeting of NF-kappaB Signaling Pathway, other Signaling Pathways and Epigenetics in Therapy of Multiple Myeloma
Cardiovascular & Hematological Disorders-Drug Targets One Special Question to Start with: Can HIF/NFkB be a Target in Inflammation?
Endocrine, Metabolic & Immune Disorders - Drug Targets Discovery of Structural Prospects of Imidazo[1,5-a]pyrazine Derivatives as BTK Inhibitors Against Cancer: A Computational Study
Letters in Drug Design & Discovery Role of Genetics and Epigenetics in Mucosal, Uveal, and Cutaneous Melanomagenesis
Anti-Cancer Agents in Medicinal Chemistry The Chlorophyll Catabolite Pheophorbide a as a Photosensitizer for the Photodynamic Therapy
Current Medicinal Chemistry HOXB7 and Hsa-miR-222 as the Potential Therapeutic Candidates for Metastatic Colorectal Cancer
Recent Patents on Anti-Cancer Drug Discovery Antiphospholipid Antibody-Mediated Thrombotic Mechanisms in Antiphospholipid Syndrome: Towards Pathophysiology-Based Treatment
Current Pharmaceutical Design Molecular Phenotyping of Mouse Mutant Resources by RNA Expression Profiling
Current Genomics Current Perspective of Natural Alkaloid Carbazole and its Derivatives as Antitumor Agents
Anti-Cancer Agents in Medicinal Chemistry The Epidermal Growth Factor Receptor as a Therapeutic Target in Glioblastoma Multiforme and other Malignant Neoplasms
Anti-Cancer Agents in Medicinal Chemistry Harnessing the Tumor Suppressor Function of FOXO as an Alternative Therapeutic Approach in Cancer
Current Drug Targets The Impact of Molecularly Targeted Therapies Upon the Understanding of Leukemogenesis and the Role of Hematopoietic Stem Cell Transplantation in Acute Promyelocytic Leukemia
Current Stem Cell Research & Therapy Tumor Necrosis Factor-α-Mediated Pulmonary Endothelial Barrier Dysfunction
Current Respiratory Medicine Reviews